Determinants of Ceftriaxone Clearance by Continuous Venovenous Hemofiltration and Hemodialysis

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Pharmacotherapy

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1592/phco.20.7.635.35170PMID 10853618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clearance of ceftriaxone in critical care patients with acute renal failure

  2005cited by this paper
• Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose

  2004cited by this paper
• Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes.

  1999cited by this paper
• Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.

  1998cited by this paper
• The Pharmacodynamics of β-Lactams

  1998cited by this paper
• The pharmacodynamics of beta-lactams.

  1998cited by this paper
• Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United States

  1998cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper
• Drug dosing adjustments during continuous renal replacement therapies.

  1998cited by this paper
• A Primer on Continuous Renal Replacement Therapy for Critically Ill Patients

  1998cited by this paper
• The Pharmacodynamics of b-Lactams

  1998cited by this paper
• Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.

  1998cited by this paper
• Transport characteristics of the slow therapies: implications for achieving adequacy of dialysis in acute renal failure.

  1997influential reference
• Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

  1997cited by this paper
• Continuous Renal Replacement Therapies: Evolution Towards a New Era

  1996cited by this paper
• Management of Drug Dosing in Continuous Renal Replacement Therapy

  1996cited by this paper
• Pharmacokinetics of Ceftriaxone in Patients Undergoing Continuous Veno‐Venous Hemofiltration

  1996cited by this paper
• The role of continuous renal replacement therapy in the future treatment of acute renal failure

  1996cited by this paper
• Drug administration in critically ill patients with acute renal failure.

  1995cited by this paper
• Clinical Pharmacokinetics During Continuous Haemofiltration

  1994cited by this paper
• Dialysate and blood flow dependence of diffusive solute clearance during CVVHD.

  1992cited by this paper
• Solute clearance in continuous venovenous hemodialysis. A comparison of cuprophane, polyacrylonitrile, and polysulfone membranes.

  1992cited by this paper
• Evaluation and first validation study on a simplified drug dosage algorithm for multiple organ failure patients.

  1992cited by this paper
• Ceftriaxone pharmacokinetics during continuous arteriovenous haemofiltration.

  1991cited by this paper
• The role of convection during simulated continuous arteriovenous hemodialysis.

  1991cited by this paper
• Ceftriaxone pharmacokinetics during continuous arteriovenous haemofiltration

  1991cited by this paper
• Clinical pharmacokinetics: Concepts and applications (2nd edn.)

  1989cited by this paper
• Removal of Cephalosporins by Continuous Arteriovenous Ultrafiltration (CAVU) and Hemofiltration (CAVH)

  1989cited by this paper
• Effect of CAVH membrane types on drug-sieving coefficients and clearances.

  1986cited by this paper
• Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment

  1984cited by this paper

• Ceftriaxone Pharmacokinetics and Pharmacodynamic Target Attainment for Three Pediatric Patients Receiving Continuous Kidney Replacement Therapy.

  2024cites this paper
• Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study)

  2022cites this paper
• An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review

  2022cites this paper
• Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy

  2021cites this paper
• Ceftriaxone-induced Encephalopathy: A Pharmacokinetic Approach

  2021cites this paper
• Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial

  2019cites this paper
• 291 – Pharmacokinetic-Pharmacodynamic Basis of Optimal Antibiotic Therapy

  2018cites this paper
• Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy

  2017cites this paper
• Antibiotic Dosing During Continuous Renal Replacement Therapy (CRRT)

  2016cites this paper
• Drug Use, Dosing, and Toxicity in Renal Disease

  2016cites this paper
• Drug Removal by CRRT and Drug Dosing in Patients on CRRT

  2015cites this paper
• Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy

  2015cites this paper
• Principles and Operational Parameters to Optimize Poison Removal with Extracorporeal Treatments

  2014cites this paper
• Antibiothérapie au cours de l’épuration extrarénale continue en réanimation

  2014cites this paper
• Prolonged ceftriaxone‐induced immune thrombocytopenia due to impaired drug clearance: a case report

  2013cites this paper
• Simplified Measurement of Middle Molecular Toxin Removal During Continuous Therapies

  2013cites this paper
• Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal Replacement Therapy

  2012cites this paper
• Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review

  2012cites this paper
• Niveau de preuve du suivi thérapeutique pharmacologique de la ceftriaxone.

  2012cites this paper
• [Study of factors affecting drug extraction during continuous hemofiltration and hemodiafiltration, and the contribution of extraction to systemic clearance].

  2012cites this paper
• Understanding Renal Replacement Therapy and Dosing of Drugs in Pediatric Patients with Kidney Disease

  2012cites this paper
• Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

  2012cites this paper
• Effect of Salmonella thyphymurium Infection on the Pharmacokinetics of Ceftriaxone in Sokoto Red Goats

  2011cites this paper
• Principles of Antibacterial Dosing in Continuous Renal Replacement Therapy

  2010cites this paper
• Free concentration and protein-binding ratio of ceftriaxone in cerebrospinal fluid in paediatric patients with purulent meningitis caused by Haemophilus influenzae type b.

  2010cites this paper
• Continuous-Infusion β-Lactam Antibiotics During Continuous Venovenous Hemofiltration for the Treatment of Resistant Gram-Negative Bacteria

  2009cites this paper
• Principles of antibacterial dosing in continuous renal replacement therapy

  2009cites this paper
• Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption.

  2009cites this paper
• Ertapenem clearance during modeled continuous renal replacement therapy

  2008influential citation
• CHAPTER 64 – Drug Use and Dosage in Renal Failure

  2008cites this paper
• Continuous venovenous hemofiltration in the critically ill

  2007cites this paper
• Pharmacokinetic Considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy

  2007cites this paper
• In vitro AN69 and Polysulphone Membrane Permeability to Ceftazidime and in vivo Pharmacokinetics during Continuous Renal Replacement Therapies

  2007cites this paper
• Prescription of antimicrobial agents in patients undergoing continuous renal replacement therapy

  2007cites this paper
• Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing

  2006cites this paper
• Elimination of Piperacillin and Tazobactam by Renal Replacement Therapies with AN69 and Polysulfone Hemofilters: Evaluation of the Sieving Coefficient

  2006cites this paper
• Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

  2005cites this paper
• Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical Pharmacy.

  2005cites this paper
• Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.

  2005cites this paper
• Introduction aux thérapies continues de remplacement rénal et principes d’ajustement des posologies des médicaments

  2004cites this paper
• Drug Dosing During Intermittent Hemodialysis and Continuous Renal Replacement Therapy

  2004cites this paper
• Principles of drug administration in children receiving renal replacement therapy

  2004cites this paper
• Pharmacokinetics of Levofloxacin During Continuous Venovenous Hemodiafiltration and Continuous Venovenous Hemofiltration in Critically Ill Patients

  2002cites this paper
• The Acute Dialysis Quality Initiative--part V: operational characteristics of CRRT.

  2002cites this paper
• Acute Dialysis Quality Initiative Workgroup 5 Operational Characteristics Timothy Bunchman

  2001cites this paper